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In Brief
Opioid neuropeptides and their receptors
are prominent in striatal compartments
known as patches (striosomes) and
matrix. We show that enkephalin
facilitates cortically driven action
potential firing selectively in mu opioid
receptor-rich patches of the dorsal
striatum through a disinhibitory
mechanism that is dominated by the delta
opioid receptor.
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Opioid neuropeptides and their receptors are evolu-
tionarily conserved neuromodulatory systems that
profoundly influence behavior. In dorsal striatum,
which expresses the endogenous opioid enkephalin,
patches (or striosomes) are limbic-associated sub-
compartments enriched in mu opioid receptors.
The functional implications of opioid signaling in
dorsal striatum and the circuit elements in patches
regulated by enkephalin are unclear. Here, we exam-
ined how patch output is modulated by enkephalin
and identified the underlying circuit mechanisms.
We found that patches are relatively devoid of parval-
bumin-expressing interneurons and exist as self-
contained inhibitory microcircuits. Enkephalin sup-
presses inhibition onto striatal projection neurons
selectively in patches, thereby disinhibiting their
firing in response to cortical input. The majority of
this neuromodulation is mediated by delta, not mu-
opioid, receptors, acting specifically on intra-striatal
collateral axons of striatopallidal neurons. These
results suggest that enkephalin gates limbic informa-
tion flow in dorsal striatum, acting via a patch-spe-
cific function for delta opioid receptors.
INTRODUCTION
The striatum is the principal input nucleus of the basal ganglia,
a group of brain nuclei critical for generating purposeful move-
ments and reinforcing behaviors that maximize reward. Many
aspects of basal ganglia and striatal circuitry, including neuro-
chemical markers and projection patterns, are conserved across
vertebrates (Reiner et al., 1998; Stephenson-Jones et al., 2012).
In particular, the opioid peptide enkephalin (enk) is selectively
expressed by striatopallidal neurons in birds, fish, andmammals,
suggesting that it mediates a highly conserved function in the
basal ganglia (Reiner, 2010).
Enk-expressing striatopallidal neurons, also known as indirect
pathway striatal projection neurons (iSPNs), are distinct from
striatonigral neurons of the direct pathway (dSPNs), which
instead express dynorphin and substance P. Together, theseNeGABAergic projection neurons comprise 90% of all striatal
neurons, are physically intermixed throughout striatum, and ac-
count for all striatal output. In rodents, cats, and primates, opioid
peptide and receptor expression patterns demarcate a second,
mesoscale organization of the striatum consisting of subdivi-
sions into patch (or striosome) and matrix compartments. The
patch compartment occupies 10%–20% of the striatal volume
and expresses high levels of the mu opioid receptor (MOR),
which is relatively absent from the surrounding matrix (Herken-
ham and Pert, 1981; Pert et al., 1976; Ragsdale and Graybiel,
1981). In contrast, enk, an endogenous ligand for MORs, is en-
riched in the matrix over patches in mice (Koshimizu et al.,
2008). Since the dorsal striatum lacks beta-endorphin (Khacha-
turian et al., 1985), enk is likely the primary endogenous ligand for
MORs in patches. Because patches exist as an interconnected
tubular labyrinth coursing through the matrix (Desban et al.,
1993; Graybiel and Ragsdale, 1978), enk signaling may repre-
sent a central means of communication between striatal patch
and matrix compartments.
Several features of patch and matrix circuitry suggest that
they operate in parallel to mediate distinct functions. First, excit-
atory inputs to each compartment are segregated according to
cortical area, with patches preferentially innervated by limbic-
associated cortical regions and matrix receiving biased innerva-
tion from sensorimotor cortices (Donoghue and Herkenham,
1986; Gerfen, 1984; Goldman-Rakic, 1982; Ragsdale and Gray-
biel, 1981). Second, the dendrites and local axon collaterals of
SPNs conform to compartmental boundaries (Kawaguchi et al.,
1989). Lastly, dSPNs in patches project directly to dopaminergic
neurons in the substantia nigra pars compacta (SNc), whereas
matrix dSPNs project to GABAergic neurons of basal ganglia
output nuclei, the substantia nigra pars reticulate, and the endo-
peduncular nucleus (Fujiyama et al., 2011; Gerfen, 1984; Wa-
tabe-Uchida et al., 2012). Thus, patch and matrix compartments
are proposed to operate as independent and functionally sepa-
rate microcircuits with distinct inputs, local circuitry, and out-
puts. These anatomical relationships are consistent with the
implication of patches in experience-based locomotor learning
and reward-guided behavior (Canales and Graybiel, 2000; Fried-
man et al., 2015; Lawhorn et al., 2009; White and Hiroi, 1998).
Despite the abundance of enk in striatum and the conspicuous
expression of MORs in patches, the functional consequence of
enk action in patches versus matrix is not known. The sole study
of opioid signaling in patches observed MOR-mediated sup-
pression of both excitatory and inhibitory synaptic transmissionuron 88, 1227–1239, December 16, 2015 ª2015 Elsevier Inc. 1227
A
Pdyn-EGFP overlay
B
anti-MOR
Pdyn-EGFP/anti-NeuN Drd1a-tdTomato/anti-NeuN overlay
500 µm
100 µm
D NeuN+ cells
n.s.
0
1000
2000
3000
4000
5000
# 
ce
lls
 / 
m
m
2
pa
tch
ma
trix
SOM+ cells
# 
ce
lls
 / 
m
m
2
pa
tch
ma
trix
0
20
40
60
80
n.s.
pa
tch
ma
trix
# 
ce
lls
 / 
m
m
2
PV+ cells
*
0
20
40
60
80
C
%
 o
f N
eu
N
+ 
ce
lls
pa
tch
ma
trix
0
20
40
60
80
*
Drd1a-tdTomato+
Figure 1. Visualization of Patch and Matrix
Compartments in Pdyn-EGFP Transgenic
Mice
(A) Fluorescence mosaic image of a coronal sec-
tion of a Pdyn-EGFP (green, left) mouse im-
munolabeled against theMOR (red, middle). EGFP
expression closely matches the distribution of
MOR-rich patches (right). This mosaic image was
acquired and generated on an Olympus VS120
microscope.
(B) Confocal fluorescence image of a striatal patch
(green) in a coronal slice of a Pdyn-EGFP (green)
and Drd1a-tdTomato (red) double transgenic
mouse immunolabeled against the neuronal
marker NeuN (blue). EGFP is expressed in patches
only in dSPNs, which express tdTomato (right).
(C) Quantification of Drd1a-tdTomato+ cells in
patches and matrix. The percentage of NeuN+
cells expressing tdTomato was higher in patches
than in the matrix. Bars graphs indicate the mean
(± SEM). *p < 0.05 using a two-tailed Mann-Whit-
ney U test.
(D) Quantification of cell density in patch and
matrix compartments. Cell classes were im-
munolabeled for identification in sections from
Pdyn-EGFP mice. No significant difference in the
density of NeuN+ cells (left) or SOM+ interneurons
(middle) was observed, whereas PV+ interneurons
were more abundant in the matrix. Examples of
SOM and PV immunolabeling are presented in
Figure S2. Bars graphs indicate the mean (± SEM).
*p < 0.05 using a two-tailed Mann-Whitney U test.(Miura et al., 2007). However, enk also binds delta opioid recep-
tors (DORs), which appear to be uniformly expressed in striatum.
Both MORs and DORs are Gai/o-coupled GPCRs that typically
suppress cellular excitability and synaptic transmission. How
the actions of enk translate into changes in circuit output depend
on its cellular and synaptic targets and what their functional roles
are in the microcircuit. Thus, the cumulative actions of enk in
striatum remain to be determined.
In this study, we use transgenic mice that enable a priori iden-
tification of both striatal pathways (dSPN versus iSPN) and com-
partments (patch versusmatrix) to analyze themicrocircuitry and
modulation of patches in mice. Using a combination of histo-
chemical methods and targeted electrophysiological recordings
in brain slices, we defined the cellular components of the patch
microcircuit, revealed that enk functions in a compartment-spe-
cific manner, identified its cellular and receptor targets, and
determined its net functional effect on circuit output. Our results
provide a detailed understanding of the circuit mechanism by
which enk selectively modulates activity in patches and provide
critical insight into the functional relevance of enk signaling in
dorsal striatum.1228 Neuron 88, 1227–1239, December 16, 2015 ª2015 Elsevier Inc.RESULTS
Patches in the Dorsal Striatum Are
Isolated Microcircuits
Analysis of the structure and function of
striatal patches has been hindered bythe lack of tools to readily identify patches in living tissue. We
took advantage of a bacterial artificial chromosome (BAC) trans-
genicmouse in which EGFP is expressed under the control of the
promoter for prodynorphin (Pdyn). Throughout this study exper-
iments were performed in the dorsal striatum (Figure S1A) of
P28–P35 mice. EGFP expression in dorsal striatum of Pdyn-
EGFP BAC transgenic mice is largely restricted to regions of
neuropil immunohistochemically labeled for MORs (Figure 1A)
(Cui et al., 2014; Gong et al., 2003). Using EGFP expression to
identify patches, we found that they comprise 10% ± 3% of
the dorsal striatal volume (Figure S1A), similar to previous esti-
mates in several organisms (Crittenden and Graybiel, 2011).
In Pdyn-EGFP mice, EGFP expression is restricted to dSPNs,
as revealed in mice also carrying the Drd1a-tdTomato BAC (Ade
et al., 2011), in which red fluorescence labels all dSPNs (Fig-
ure 1B). EGFP was detected in 86% of tdTomato-expressing
neurons (228 of 264 cells), and there was no coexpression of
EGFP with transgenically labeled iSPNs (see Experimental Pro-
cedures; Figures S1B and S1C) or immunohistochemically iden-
tified interneuron classes (Figure S2). This high specificity and
selectivity of labeling of patch dSPNs with a marker visible in
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Figure 2. Anatomical and Functional Isola-
tion of Patch and Matrix Compartments
(A) Confocal fluorescence image of a neurobiotin-
filled dSPN located near the border within a patch.
The dendrites of this patch SPN remained within
the patch.
(B) Electrical stimulation with a small bipolar elec-
trode reveals a lack of inter-compartmental inhib-
itory synaptic connectivity. Left: IPSC amplitude
dropped dramatically when the stimulating elec-
trode was moved at equal distance from the cell
body into the matrix, as depicted in the schematic.
Right: Representative traces (average of three tri-
als) obtained with the electrode placed 70 mm
away from the recorded cell in the patch (red) and
matrix (purple).
(C) Summary plot of the IPSC amplitudes evoked
in each patch neuron by stimulation in the patch
and matrix shown as connected dots. Averages
across cells are shown in gray (mean ± SEM). *p <
0.05, one-tailed Wilcoxon signed-rank test.acute brain slices permits systematic analyses of both cellular
composition and the electrophysiological properties of striatal
patches. However, because Pdyn-EGFP incompletely labels
patch dSPNs (86%), we frequently included theDrd1a-tdTomato
transgene in order to identify all dSPNs in both compartments,
and by exclusion of tdTomato, target iSPNs.
Previous anatomical analyses have reported conflicting results
as to whether the cellular composition of patch and matrix
compartments is distinct (Besson et al., 1990; Gerfen and Young,
1988). Immunolabeling of striatal slices from Pdyn-EGFP;Drd1a-
tdTomato mice for the neuron-specific nuclear protein NeuN
(Figure 1B) revealed that dSPNs are overrepresented in
patches (patch: 60% ± 3% [245 of 417] NeuN+ neurons are
tdTomato+; matrix: 47% ± 1% [217 of 456] NeuN+ neurons are
tdTomato+; 7 images, 2 mice, p = 0.0023) (Figure 1C), although
overall neuronal density is similar across compartments (patch:
2,483 ± 295 cells/mm2; matrix: 3,305 ± 846 cells/mm2; p =
0.45) (Figure 1D).We foundnodifference in the density of cells im-
munopositive for somatostatin (SOM) (patch: 49 ± 11 cells/mm2,
n = 33 cells; matrix: 44 ± 1 cells/mm2, n = 361 cells; 4 images, 2
mice, p > 0.99) (Figure 1D). In contrast, parvalbumin (PV)-ex-
pressing cells were approximately half as abundant in patches
compared tomatrix (patch: 28 ± 7 cells/mm2, n = 27 cells; matrix:
65 ± 3 cells/mm2, n = 564 cells; 5 images, 2mice, p = 0.0079) (Fig-
ure 1D). In agreement with this, synaptophysin labeling of pre-
synaptic terminals of PV cells provided sparser innervation of
patches relative to matrix (Figure S3). Together, these data indi-
cate that patch microcircuits are enriched in dSPNs and have
reduced PV cell innervation compared to the surrounding matrix.
Anatomical data suggest that patch andmatrix compartments
have segregated local inhibitory connectivity (Kawaguchi et al.,
1989), but this has not been tested functionally. Furthermore,
several interneuron classes may break this rule (Penny et al.,
1988). High-magnification images of EGFP+ neuronal processesNeand neurobiotin-filled dSPNs confirmed that dendrites origi-
nating from cells inside patches remain within patches, even if
the cell body is near the compartment boundary (Figure 2A).
To examine whether SPNs within patches are functionally
innervated by neurons residing in the matrix, we recorded syn-
aptic currents in patch neurons under whole-cell voltage-clamp
in acute brain slices of Pdyn-EGFP mice. Inhibitory synaptic
transmission was evoked using small bipolar stimulating elec-
trodes placed in the same patch compartment as the recorded
cell and isolated pharmacologically by blocking glutamate re-
ceptors with NBQX and CPP. After obtaining a stable baseline,
the stimulating electrode was moved stepwise into the matrix,
maintaining a fixed radial distance from the soma of the re-
corded cell of 70 mm (Figure 2B). At the compartment border,
the evoked amplitude of the evoked inhibitory post-synaptic
current (IPSC) dropped rapidly with small changes in the posi-
tion of the stimulating electrode and was lost altogether in the
matrix (patch: 124 ± 24 pA; matrix: 1 ± 2 pA; n = 6 cells, p =
0.016) (Figure 2C). IPSCs recovered upon moving the electrode
back into the patch (not shown). Therefore, patches do not
receive substantial inhibition from neurons in the surrounding
matrix.
Opioid Receptors Are Expressed in SPNs of Both
Pathways
Given the synaptically isolated nature of the patch compartment,
communication between patch and matrix compartments might
be carried out by neuromodulators, which are capable of sig-
naling over substantial distances in tissue. Consistent with this
idea, enk is expressed at higher levels in the matrix than in
patches (Figure S4) (Koshimizu et al., 2008). Since patches are
highly enriched in MORs, enk may signal from the matrix into
patches. Alternatively, enk could also activate DORs, which
are expressed throughout striatum. Despite the enrichment ofuron 88, 1227–1239, December 16, 2015 ª2015 Elsevier Inc. 1229
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Figure 3. Opioid Receptor Distribution in
SPNs as Revealed by Three-Color FISH
(A) Example of staining within a patch for Prody-
norphin (Pdyn, green), the MOR (Oprm1, magenta),
and the D2 dopamine receptor (Drd2, white).
Although there is very little co-localization of Pdyn
and Drd2, Oprm1 is found with both transcripts.
Large arrowheads indicate example Pdyn+ cells,
and small arrows indicate Drd2+ cells. Nuclear
DAPI staining is omitted for clarity.
(B) Example of staining within a patch for Pdyn
(green), the DOR (Oprd1, magenta), and Drd2
(white). Oprd1 is only found in cells expressing
Drd2.
(C) Quantification of the co-expression of Drd2,
Oprm1, and Oprd1 with Pdyn. Bars represent the
mean (+SEM) percentage of Pdyn+ DAPI-stained
nuclei also expressing the indicated transcripts.
*p < 0.05 using a two-tailed Mann-Whitney U test.
Oprm1, but not Oprd1, is found in cells expressing
Pdyn.
(D) Quantification of the co-expression of Pdyn,
Oprm1, and Oprd1 with Drd2. Bars represent the
mean percentage (+SEM) of Drd2+ DAPI-stained
nuclei also expressing the indicated transcripts.
Both Oprm1 and Oprd1 are found in cells ex-
pressing Drd2.
(E) Example of staining within a patch for Pdyn
(white), Oprd1 (green), and Oprm1 (magenta).
Oprm1 and Oprd1 are co-expressed but only in
Pdyn cells. Large arrowheads indicate example
Pdyn+ cells, and small arrows indicate example
Oprd1+ cells. Summary data for (E) is presented in
Figure S6C.MORs in patches and demonstration of their expression in
dSPNs (Cui et al., 2014), which cells within the striatum express
DORs and MORs remains unclear.
Neuron classes that express MORs and DORs were identified
by fluorescence in situ hybridization (FISH) to examine the
expression of multiple mRNAs in individual cells. dSPNs and
patches were identified by labeling for Pdyn, and iSPNs were
distinguished by the labeling for Drd2. Although strongly nega-
tively correlated (Figure S5), we observed co-labeling of Pdyn
and Drd2 probes in 17%–18% of cells in patches (see Supple-
mental Experimental Procedures). Given the lack of co-labeling
of iSPNs and dSPNswith transgenicmarkers, this value likely es-
timates the false-positive co-expression rate. We therefore used
the co-labeling of Pdyn and Drd2 as a control for evaluating
opioid receptor expression in each cell class.
We quantified the number of fluorescent puncta correspond-
ing to transcripts for Oprm1 (encoding MORs) or Oprd1 (encod-
ing DORs) in dSPNs and iSPNs in both patches and matrix
(Figures 3A, 3B, and S5). Consistent with the prominence of
MOR protein in patches, Oprm1 was detected in a greater per-
centage of cells located within Pdyn-enriched patches than in
the matrix (Figure S6A). Furthermore, the number of transcripts1230 Neuron 88, 1227–1239, December 16, 2015 ª2015 Elsevier Incper cell was greater in patches than in matrix (Figure S6B). In
contrast, Oprd1 was detected uniformly in both compartments,
both in terms of the percentage of Oprd1+ cells and the number
of transcripts per cell (Figures S6A and S6B), consistent with
prior studies using radiolabeled ligands that bind DORs (for
example, Pradhan and Clarke, 2005).
Within patches most Pdyn+ dSPNs expressed Oprm1, but
not Oprd1 (Oprm1+: 78% ± 2%, n = 1622 cells, 5 images, 3
mice, p = 0.0010; Oprd1+: 13% ± 1%, n = 1,003 cells, 4 images,
2 mice, p = 0.19) (Figure 3C). In contrast, most Drd2+ iSPNs
expressed Oprd1 and only about half expressed Oprm1
(Oprd1+: 78% ± 2%, n = 1,003 cells, 4 images, 2 mice, p =
0.0028; Oprm1+: 45% ± 5%, n = 1,622 cells, 5 images, 3 mice,
p = 0.0010) (Figure 3D). These data suggest that individual iSPNs
might express both DOR andMOR in patches. Indeed, in a sepa-
rate experiment, we confirmed co-expression of Oprm1 and
Oprd1 in patch iSPNs using triple FISH for PDyn, Oprm1, and
Oprd1 (Figure 3E). The vast majority of cells expressing both
Oprm1 and Oprd1 were negative for Pdyn (Figure S6C). There-
fore, these results (tabulated in Figure S6D) suggest that the
potential GPCR targets for enk in patches are MORs and
DORs on iSPNs and MORs on dSPNs..
Enkephalin Suppresses Synaptic Inhibition in Patches
but Not Matrix
The observation that SPNs in patches express opioid receptors
raises the possibility that enk might alter the membrane excit-
ability of both dSPNs and iSPNs. To test for this, we expressed
channelrhodopsin-2 (ChR2) (Boyden et al., 2005) in SPNs and
applied enk during cell-attached recordings fromChR2-express-
ing neurons in order to preserve cytosolic signaling molecules
that may be downstream of opioid receptors. ChR2 was selec-
tively expressed in dSPNs or iSPNs by infection with Cre-depen-
dent adeno-associated virus (AAV) in the appropriate transgenic
animal. In the presence of a cocktail of antagonists for ionotropic
and metabotropic glutamate and GABA receptors, ramps of
blue light evoked trains of action potentials that progressively
increased in frequency (Figure 4A). To sensitively detect changes
in excitability, light intensities were chosen to trigger spike trains
that exhibit minimal accommodation, which typically involved a
1-s delay to the first spike and maximal instantaneous firing rates
of 30–40 Hz. After achieving stable responses, enk (leucine-
enkephalin) was applied by bath perfusion at a concentration
that strongly activates MORs and DORs (30 mM). The number
of light-evoked action potentials evoked per trial was unaffected
by 3–5min of enk application (dSPNs: 95%±10%of baseline, n =
9 cells, p = 0.44; iSPNs: 100% ± 3% of baseline, n = 6 cells, p >
0.99; p values reflect comparison of enk to baseline, see Experi-
mental Procedures) (Figure 4B). Thus, despite the expression of
opioid receptors by SPNs, enk does not directly regulate the
excitability of dSPNs or iSPNs in patches.
It is well established that MOR and DOR agonists suppress
excitatory transmission onto SPNs by 10%–30% in both
patches and matrix (Atwood et al., 2014; Blomeley and Bracci,
2011; Jiang and North, 1992; Miura et al., 2007). We therefore
focused on inhibitory synaptic transmission. In acute brain sli-
ces prepared from Pdyn-EGFP;Drd1-tdTomato mice, we ob-
tained whole-cell voltage-clamp recordings from identified
dSPNs and iSPNs located in both patches and matrix. IPSCs
were evoked electrically in the presence of NBQX and CPP
(Figure 4C), as well as the muscarinic antagonist scopolamine
to prevent potential confounds due to modulation of enk-sensi-
tive cholinergic neurons (Jiang and North, 1992; Ponterio et al.,
2013). Example IPSCs recorded from SPNs in the matrix and
patches are shown in Figure 4D, before and 3–5 min after
enk application. For each neuron, the effect on IPSC amplitude
was calculated as follows:
DIPSC= 100,ðDIPSCenk  DIPSCbaselineÞ=DIPSCbaseline:
IPSCs recorded from dSPNs in the matrix were insensitive to
enk but in patches they were strongly suppressed (matrix:
DIPSC = 6% ± 8%, n = 11, p = 0.64; patch: 54% ± 4%,
n = 19, p < 0.00010) (Figures 4E and 4F). Similar actions
were observed with methionine-enkephalin, another enkeph-
alin analog abundant in striatum, as well as with a lower con-
centration of enk (1 mM) indicating that 30 mM saturates striatal
opioid receptors (Figure S7B). IPSCs recorded from iSPNs
were also insensitive to enk in matrix and significantly sup-
pressed in patches (matrix: 3% ± 8%, n = 6, p = 0.84; patch:
36% ± 4%, n = 8, p = 0.0078) (Figure S7C), although to aNelesser extent compared to dSPNs (p = 0.0013, Figure 4F).
Therefore, suppression of inhibition by enk is robust and spe-
cific to patches. Because inhibition onto dSPNs was more
sensitive to enk, and due to their potential to influence dopa-
mine signaling in the striatum, we focused on recordings
from patch dSPNs for all subsequent studies.
Suppression of inhibition by enk was completely blocked in
the presence of opioid antagonists (DIPSC = 2% ± 2%, n =
5, Figure 4G). To determine whether this suppression is tran-
sient or a form of long-term plasticity, we chased enk from
the bath with opioid antagonists (Figure 4H). Within 5–10 min
of washout, we observed near complete recovery of the IPSC
(61% ± 11% in enk versus 6% ± 7% after washout, n = 5
cells, p = 0.031). Therefore, suppression of inhibition by enk
is an acute, reversible modulation. The locus of modulation
could be either pre- or post-synaptic, since SPNs of both path-
ways express opioid receptors. We were unable to obtain pos-
itive evidence for modulation of either the pre- or post-synaptic
terminal, as enk application did not significantly alter paired-
pulse ratios, spontaneous miniature IPSC (mIPSC) amplitude
or frequency, or GABA uncaging-evoked currents (Figures
S7D–S7G).
DORs Are the Major Receptor Target of Enkephalin in
Patches
To determine if activation ofMORmediates the actions of enk, we
examined suppression of inhibition in Pdyn-EGFP;Oprm1/
mice (Matthes et al., 1996). In these mice, which lack MORs but
retain patches (Figure 5A), enk application still strongly sup-
pressed IPSC amplitude (DIPSC = 46% ± 7%, n = 8 cells, p =
0.0039) (Figures 5B and 5C). Similarly, in Pdyn-EGFP;Oprd1/
mice (Filliol et al., 2000) patches were retained (Figure 5A) and in-
hibition was also suppressed, albeit to a lesser extent than either
wild-type or Oprm1/ conditions (DIPSC = 28% ± 5%, n = 10
cells, p = 0.0019) (Figures 5B and 5C). These results indicate that
neither receptor is strictly necessary for enk to suppress inhibition
and suggest a contribution from both MORs and DORs.
In order to assess whether either MOR or DOR activation is
sufficient to explain the effects of enk, we selectively activated
each receptor pharmacologically. SNC-80 exhibits >10,0003
selectivity for DORs overMORs (Knapp et al., 1996), allowing se-
lective activation of DORs in brain slices. Although DAMGO is the
prototypical MOR-selective agonist, we found that DAMGO
application reduced inhibition in Pdyn-EGFP;Oprm1/ mice
when applied at 1 mM but not 300 nM (Figures S8A and S8B).
The effects of 1 mM DAMGO in the Pdyn-EGFP;Oprm1/
mice were blocked by the highly selective DOR antagonist
TIPP-Psi (3 mM, Figures S8A and S8B), at a concentration we
independently verified to exhibit selectivity for DORs (Figures
S8C and S8D). We therefore used 300 nM DAMGO in the pres-
ence of 3 mM TIPP-Psi to selectively probe MORs. Under this
stringent condition, DAMGO application suppressed inhibition
by 22% ± 4% (n = 9 cells, p = 0.0019), confirming that MOR acti-
vation is sufficient to suppress inhibition (Figure 5C). DOR ago-
nism by SNC-80 (500 nM), however, produced an approximately
2-fold larger effect (DIPSC = 41 ± 8%, n = 11 cells, p = 0.0010)
(SNC-80 versus DAMGO, p = 0.032), whichwas blocked by 3 mM
TIPP-Psi (Figure S8E). Consistent with additive contributionsuron 88, 1227–1239, December 16, 2015 ª2015 Elsevier Inc. 1231
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Figure 4. Enkephalin Suppresses Inhibition onto dSPNs and iSPNs in Patches but Not Matrix
(A) Cell-attached recordings of action potential firing from a dSPN (left) and iSPN (right) in the absence (top) and presence (bottom) of enk (30 mM), evoked by a 2-s,
473-nm blue light ramp. Action potential firing is unchanged by enk. ChR2 was targeted to dSPNs or iSPNs using the following transgenic animals: Drd1a-
Cre;Pdyn-EGFP for dSPNs; Adora2A-Cre;Pdyn-EGFP for iSPNs; and Dlg3-Cre;Drd1a-tdTomato;Ai32 for either (see Figure S7A).
(B) Summary data showing average number of spikes per trial evoked during the 2-s stimulus in the presence of enk normalized to baseline. Averages from each
cell are shown as open circles. The superimposed bars indicate the mean (± SD).
(C) Schematic illustrating the experimental configuration. Whole-cell voltage-clamp recordings of dSPNs or iSPNs were obtained in the patch or matrix com-
partments in acute brain slices from Pdyn-EGFP;Drd1a-tdTomato mice. Glass stimulating electrodes were placed in the same compartment within 100 mmof the
recorded cell.
(legend continued on next page)
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Figure 5. DORs, Not MORs, Dominate the
Suppression of Inhibition by Enkephalin
(A) Fluorescence mosaic images of EGFP
expression in coronal sections taken from Pdyn-
EGFP;Oprm1/ (left) and Pdyn-EGFP;Oprd1/
(right) mice. In both cases, patches are present
and do not display gross abnormalities. Mosaic
images were acquired and generated on an
Olympus VS120 microscope.
(B) Average normalized IPSC amplitudes (± SEM)
over time during enk application for neurons from
Pdyn-EGFP;Oprm1/ (gray) and Pdyn-EGFP/
Oprd1/ (black) mice. In both cases IPSCs were
suppressed by enk.
(C) Summary plot of the normalized average IPSCs
in enk measured in Pdyn-EGFP;Oprm1/ and
Pdyn-EGFP;Oprd1/ mice as well as in wild-type
Pdyn-EGFP mice in the presence of the MOR
agonist DAMGO, the DOR agonist SNC-80, the
two combined, or enk (from Figure 4F). Although
both DAMGO and SNC-80 significantly sup-
pressed IPSCs, SNC-80 had a larger effect. The
actions of co-applied SNC-80 and DAMGO were
similar to enk. Averages from each cell are shown
as open circles. The superimposed bars indicate
the mean (± SEM). *p < 0.05 using a two-tailed
Mann-Whitney U test.from both DORs andMORs, following DOR activation with SNC-
80, addition of DAMGO (1 mM) further suppressed inhibition
(59% ± 4%, n = 12 cells, p = 0.00025), to an extent indistin-
guishable from enk (p = 0.39). These results indicate that enk
suppresses inhibition onto patch dSPNs predominately via
DORs, with a smaller contribution from MORs.
iSPN Inputs to dSPNs Are the Major Cellular Target of
Enkephalin in Patches
Patch SPNs receive inhibitory inputs from multiple classes of
neurons, including other SPNs and GABAergic interneurons,
any of which might be modulated by enk. To identify the inhibi-
tory inputs to dSPNs that are sensitive to enk, we bred mice
that express Pdyn-EGFP along with Cre recombinase in specific
striatal cell classes. We used Cre-dependent AAVs to express
ChR2 in Cre-expressing neurons and examined the effect of
enk on ChR2-evoked IPSCs. We were unable to reliably evoke
IPSCs in patches using two strains of mice expressing Cre un-
der PV promoters (Pvalb-IRES-Cre, Pvalb-2A-CreERT2-D, not
shown), possibly due to the relative lack of innervation of patches
by fast-spiking interneurons (Figures 1 and S3).(D) Example of electrically evoked IPSCs recorded in the matrix (left) or patch
are shown.
(E) Average normalized IPSC amplitude (± SEM) over time during enk application f
strongly suppressed in patches but not matrix. For iSPNs, see Figure S7C.
(F) Summary data showing average baseline normalized IPSCs measured in the
(matrix) and circles (patch). The superimposed bars indicate the mean ± SEM. *p
(G) Average normalized IPSC amplitudes (± SEM) over time for dSPNs in patches
naloxone; 3 mM SDM25N). Enk did not suppress inhibition in the presence of op
(H) Example recording from a dSPN showing that the enk effect was reversed w
(I) Summary plot of the baseline-normalized average IPSCs evoked in dSPNs in
(± SEM) for individual neurons are shown as connected dots and across cells in
NeGABAergic synaptic currents were pharmacologically isolated
and optogenetically evoked using blue light flashes. GABAergic
IPSCs from SOM cells were not suppressed by enk (DIPSC =
4% ± 3%, n = 8 cells, p = 0.35). Inputs from dSPNs and iSPNs
were suppressed by enk (dSPNs: 32% ± 8%, n = 12 cells,
p = 0.0010; iSPNs: 68% ± 5%, n = 10 cells, p = 0.0020), with
iSPN inputs responding more strongly than dSPN inputs (p =
0.0032) (Figures 6A–6C).
The FISH analysis indicated that MORs are present in both
dSPNs and iSPNs and that DORs are exclusively expressed in
iSPNs. We hypothesized that suppression of iSPN inputs onto
dSPNs is mediated by DORs and possibly MORs, whereas
that of dSPN inputs onto dSPNs is mediated by MORs alone.
To test this, we examined each class of inputs using the selective
agonists described previously (Figure 5). Consistent with the
FISH findings, DAMGO slightly suppressed inhibition from both
dSPN and iSPN inputs (dSPNs: 27% ± 5%, n = 10 cells, p =
0.0010; iSPNs: 17% ± 5%, n = 10 cells, p = 0.0059) (Figure 6).
In contrast, SNC-80 had no effect on dSPN inputs but strongly
suppressed iSPN inputs (dSPNs: 6% ± 3%, n = 11 cells, p =
0.07; iSPNs: 48 ± 7%, n = 6 cells, p = 0.016). Supporting the(right) before (black) and after (gray) application of enk. Single trial examples
or dSPNs in the matrix (squares) and patch (circles) compartments. IPSCswere
presence of enk. Averages from individual cells are shown as open squares
< 0.05 using a two-tailed Mann-Whitney U test.
during enk application in the presence of an opioid antagonist cocktail (3 mM
ioid antagonists.
ith an opioid antagonist cocktail (3 mM naloxone; 3 mM SDM25N).
the presence of enk and after reversal with opioid antagonists. The averages
gray. *p < 0.05, one-tailed Wilcoxon signed-rank test.
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Figure 6. Optogenetic Activation of Striatal
Cell Classes Reveals that Inhibition Arising
from dSPNs and iSPNs Is Suppressed by
Enkephalin in Patches
(A) Synaptic inhibition originating from SOM in-
terneurons is not suppressed by enk. Top: Sche-
matic depicting selective optogenetic activation of
SOM interneurons in Sst-Cre;Pdyn-EGFP mice
during whole-cell voltage-clamp recordings from
dSPNs in patches. Bottom: Summary plot of the
normalized average IPSCs measured in enk.
Throughout this figure, averages from each cell are
shown as open circles. The superimposed bars
indicate the mean (± SEM).
(B) Synaptic inhibition originating from dSPNs is
suppressed by enk and DAMGO, but not SNC-80.
Top: Schematic depicting selective optogenetic
activation of dSPNs in Drd1a-Cre;Pdyn-EGFP
mice during whole-cell voltage-clamp recordings
from dSPNs in patches. Bottom: Summary plot of the normalized average IPSC measured in enk, DAMGO, and SNC-80.
(C) Synaptic inhibition originating from iSPNs is suppressed by enk, DAMGO, and SNC-80. Top: Schematic depicting selective optogenetic activation of iSPNs in
Adora2A-Cre;Pdyn-EGFP mice during whole-cell voltage-clamp recordings from dSPNs in patches. Bottom: Summary plot of the normalized average IPSC
measured in enk, DAMGO, and SNC-80. SNC-80 had a significantly greater effect than DAMGO. *p < 0.05 using a two-tailed Mann-Whitney U test.lack of DORs in dSPNs, the action of DAMGO on dSPN inputs
was sufficient to account for the action of enk (p = 0.91). This
was not the case for suppression of iSPN input, where SNC-80
dominated the effect over DAMGO (SNC-80 versus DAMGO,
p = 2.03 104). These data support a local circuit model in which
enk suppresses inhibition onto dSPNs predominantly via DORs
on iSPN inputs, and to a lesser extent via MORs influencing
both iSPN and dSPN inputs.
Enkephalin Disinhibits Patch dSPNs
Given that enk does not directly modulate SPN firing but
strongly reduces SPN to SPN collateral inhibition, we hypothe-
sized that the net outcome of enk signaling in patches is disin-
hibition during prolonged excitatory drive. To investigate this
possibility, we stimulated network activity by optogenetically
driving cortico-striatal excitatory inputs and measured the ac-
tions of enk on SPN output (Figure 7A). Whole-cell voltage-
clamp recordings revealed IPSCs at the reversal potential for
glutamatergic transmission, which were strongly suppressed
by enk (DIPSC = 57% ± 5%, n = 6 cells, p = 0.016) to a degree
similar to that measured using electrical stimulation locally in
patches (p = 0.72) (Figures 7B and 7C). Confirming that this in-
hibition was indeed mediated by excitatory transmission-driven
disynaptic inhibition, NBQX and CPP eliminated the IPSC
(reduced to 6% ± 2% of baseline, n = 6 cells, p = 0.016, Figures
7B and 7C).
Because opioids have been reported to reduce glutamate
release in both patches and matrix (Atwood et al., 2014; Jiang
and North, 1992; Miura et al., 2007), suppression of excitation
might counteract suppression of inhibition and prevent the pre-
dicted facilitation of spiking in patches by enk. Therefore, we
measured the consequence of enk application on action poten-
tial firing induced by cortico-striatal activation. Whole-cell cur-
rent-clamp recordings from dSPNs in patches were used
to monitor the responses to five blue light flashes delivered at
20–25 Hz. This stimulus typically elicited a single spike in1234 Neuron 88, 1227–1239, December 16, 2015 ª2015 Elsevier Incresponse to the first flash, which was followed by subthreshold
EPSPs (Figure 7D). On average, the number of action potentials
per trial increased 3–5 min after enk application (1.11 ± 0.07
spikes during baseline versus 1.94 ± 0.36 in enk, n = 6 cells,
p = 0.031). When discernable, the amplitude of a superimposed
feedback IPSP, presumably arising from adjacent SPNs that also
fired in response to cortico-striatal stimulation, also decreased
(Figure 7E). In contrast, enk did not change the response of
dSPNs located in the matrix to the same stimulus (1.03 ± 0.03
spikes during baseline versus 0.95 ± 0.12 in enk, n = 5 cells,
p = 0.75, Figure 7F), consistent with selective suppression of in-
hibition in patches. Therefore, the net consequence of enk on
striatal output is disinhibition of dSPNs in patches, enabling
these neurons to better follow trains of excitatory drive from cor-
tex. This disinhibition is specific to patches and thus represents a
mechanism for opioid action to shift the balance of activity be-
tween striatal compartments to favor patches.
DISCUSSION
In this study, we used Pdyn-EGFP mice to identify patches
and dSPNs in dorsal striatum. Our observations in mice
reveal distinct microcircuitry in patches and provide functional
evidence for compartmentalized synaptic transmission. We
further examined the actions of the endogenous opioid neuro-
peptide enk on synaptic transmission and microcircuit output.
Our anatomical and functional data concordantly confirm that
MORs are prominent in dSPNs and that they mediate compart-
ment-specific suppression of inhibition in patches. Surprisingly,
our studies uncovered amajor role for DORs in the compartmen-
talized actions of enk, despite their uniform expression in stria-
tum.We pinpointed iSPNs as themajor cellular target of enk pre-
dominately via its activation of DORs, and to a lesser extent via
activation of MORs. We further demonstrated that this disinhibi-
tory pathway leads to a net increase in dSPN firing in patches,
highlighting the importance of DOR and inhibitory collaterals in.
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Figure 7. Enkephalin Disinhibits dSPNs in
Patches
(A) Schematic depicting optogenetic activation of
the striatal microcircuit in brain slice by driving cor-
ticostriatal inputs in Emx1-Cre;Pdyn-EGFP;Drd1a-
tdTomato;Ai34 mice.
(B) Disynaptic inhibition in patches is suppressed
by enk. Example IPSCs in the absence (baseline,
black) and presence of enk (gray), and after the
addition of NBQX and CPP (orange) to block
excitatory transmission.
(C) Summary plot of the normalized average IPSC
measured in enk and NBQX+CPP. Averages from
each cell are shown as open circles. The super-
imposed bars indicate the mean (± SEM).
(D) Synaptically driven action potentials are facili-
tated by enk. Example current-clamp recording
from a patch dSPN that was stimulated by five blue
light flashes (20 Hz) before (black) and after (gray)
enk application. Data were acquired every 20 s.
(E) Superimposed single-trial example responses
to the blue light stimulus before (black) and after
(gray) enk application. In this example, suppres-
sion of the co-incident IPSP by enk can be
observed.
(F) dSPNs are disinhibited in the patch, but not
matrix compartment. Summary plots of the average
number of spikes per trial during the baseline period
and after enk application, recorded from cells
located in the patch (left) and matrix (right) com-
partments. The averages (± SEM) for individual
neurons are shown as connected dots and across
cells in gray. *p < 0.05, two-tailed Wilcoxon signed-
rank test.shaping cortically driven striatal output. These findings are
graphically summarized in Figure 8.
Patch Microcircuitry
We characterized the circuitry of patches and conducted exper-
iments that functionally probe synaptic compartmentalization.
We found that cellular composition differs between patches
and matrix with the former having higher dSPN density and a
conspicuous under-representation of PV+ interneurons. Further-
more, using several transgenic mouse lines, we were unable to
reliably obtain synaptic responses in patch SPNs following stim-
ulation of PV+ interneurons, suggesting a lack of PV innervation
of patch SPNs. The functional implications of this difference
require further investigation.
SPN axon collaterals have been reconstructed and shown to
respect compartmental boundaries (Kawaguchi et al., 1989;
Penny et al., 1988). In contrast, SOM and PV interneurons
seem to localize near the borders, with their axons (SOM)
(Rushlow et al., 1996) and dendrites (PV) (Cowan et al.,
1990; Kubota and Kawaguchi, 1993) innervating both patches
and matrix. However, our results indicate that the vast ma-
jority of synaptic inhibition in patches arises from within the
compartment. These results also suggest that axons of other
inhibitory neurons, such as pallidostriatal projections and
axons of SPNs leading out of striatum, do not generally cross
patch/matrix boundaries.NeOpioid Regulation of Inhibition in Patches
To understand the consequences of enk signaling, we systemat-
ically identified sites of enk action in the patch microcircuit. The
intrinsic excitability of neither dSPNs nor iSPNs was sensitive to
enk, despite their high expression of opioid receptors. As ex-
pected, we observed patch-specific suppression of inhibition,
but unlike prior studies (Miura et al., 2007), we found that primar-
ily DORs rather than MORs mediate this opioid effect.
The observed pathway distribution of opioid receptors in
dSPNs and iSPNs in patches provides insights inaccessible in
prior anatomical (Cui et al., 2014; Guttenberg et al., 1996;
Oude Ophuis et al., 2014) and biochemical (Lindskog et al.,
1999; Noble and Cox, 1995) studies that did not distinguish be-
tween compartments. While these studies established a clear
association between MORs in dSPNs and DORs in iSPNs, they
did not report evidence of MORs in iSPNs, presumably due to
oversampling of SPNs in the more prominent matrix compart-
ment. By targeting patches for analysis, we observed co-expres-
sion of MORs and DORs in iSPNs and verified this functionally.
This result highlights that classic models of striatal pathway dif-
ferences are not generally applicable to patches and requires
that patch iSPNs be considered in future studies concerning
MOR function in the striatum. Mapping the opioid receptors
to dSPNs and iSPNs also provided further insight into the func-
tional site of action of enk. The selective expression of DORs
in iSPNs indicates a presynaptic site of action, although theuron 88, 1227–1239, December 16, 2015 ª2015 Elsevier Inc. 1235
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Figure 8. Summary Model of Enkephalin
Modulation of the Patch Microcircuit
Patches and matrix receive different cortical in-
puts and locally process information with different
contributions from PV interneurons. Local inhibi-
tion suppresses repetitive, high-frequency firing in
response to cortical drive. By reducing inhibition
from SPN collaterals via activation of MORs on
dSPNs and iSPNs and DORs on iSPNs, enkeph-
alin facilitates information flow through patches,
but not matrix.electrophysiological data presented do not conclusively support
either a pre- or post-synaptic mechanism. Because MORs are
expressed in both pathways, similar inferences cannot be
made and the site of action of this receptor remains to be
determined.
One major question that emerges from our study is how
DOR-mediated modulation of inhibition is restricted to iSPN
collaterals in patches. Analysis by FISH clearly demonstrates
uniform expression of DORs throughout the striatum, with
neither the number ofOprd1+ cells nor the number of transcripts
expressed in each cell being different between compartments.
All prior anatomical studies using radiolabeled DOR ligands
also report a uniform distribution. Yet in the matrix we observed
no suppression of electrically evoked inhibition or facilitation of
spiking in response to cortical drive in the presence of enk (but
see Jiang and North, 1992; Miura et al., 2007). The cellular mech-
anism underlying this compartmental specificity requires further
investigation.
We and others have noted relatively low expression levels of
enk in patches in comparison to matrix in mice (Figure S4) (Gray-
biel and Chesselet, 1984; Koshimizu et al., 2008; Tajima and Fu-
kuda, 2013). Although this distribution supports a role for enk in
intercompartmental communication, it is possible that dynor-
phin, a kappa opioid receptor agonist that can activate MOR
and DOR with substantial potency (Pennock and Hentges,
2014; Toll et al., 1998; Zhang et al., 1998), serves as a local ligand
in patches. Additionally, prodynorphin contains a copy of leu-
enk. However, the vast majority of dynorphin appears to be
transported out of striatum to axonal release sites in the substan-
tia nigra (Besson et al., 1990; Chesselet and Graybiel, 1983;
Fallon and Ciofi, 1990). Nonetheless, it is possible that enk
and dynorphin both disinhibit patch SPNs via inter- and intra-
compartmental signaling.
Implications for Striatum-Dependent Behavior
The anatomical evidence that patch dSPNs provide direct input
to SNc dopamine neurons suggests that patches are uniquely1236 Neuron 88, 1227–1239, December 16, 2015 ª2015 Elsevier Inc.positioned to control dopamine release
in striatum. Our findings imply that enk
could indirectly influence striatal dopa-
mine levels by selectively modulating
patch output. Indeed, there is evidence
that local enk administration promotes
dopamine metabolism in dorsal striatum
(Biggio et al., 1978). Such an interactionwould provide a route for integration of sensorimotor and limbic
signals.
Our results suggest that future studies into the behavioral sig-
nificance of opioids in dorsal striatum should consider effects via
DORs. Due to the clear role of MORs in addiction, most prior
studies into opioid signaling in striatum have focused on MORs
in the context of behavioral reinforcement (Burkett et al., 2011;
Cui et al., 2014; DiFeliceantonio et al., 2012). However, local
administration of opioids is not inherently rewarding in dorsal
striatum (Bals-Kubik et al., 1993; van der Kooy et al., 1982).
Optogenetic stimulation and inhibition of excitatory inputs to
dorsomedial patches was recently shown to impact cost-benefit
decision making in rats (Friedman et al., 2015). Critically, the in-
fluence of stimulation was context dependent. Our data raise the
possibility that by sensitizing patch SPNs to excitatory input
through disinhibition, opioids could contribute to such deci-
sion-making processes by providing a context signal.
In this study, we examined opioid modulation in the dorsal
striatum, with the expectation that enk actions through MORs
would provide compartment-specificity. Instead, we found only
a minor role for MORs, despite their striking abundance in
patches, suggesting that the primary role of MORs in patches
is not to mediate suppression of inhibition. Indeed, MORs are
most prominently localized in SPN dendrites and dendritic
spines (Wang et al., 1996). Given the lack of compartment-spe-
cific modulation of excitatory transmission and the relatively
weak MOR-dependent modulation of inhibition, we speculate
that these post-synaptic receptors may play a role in the gating
of synaptic plasticity and tuning cellular responses to other neu-
romodulators such as dopamine.
EXPERIMENTAL PROCEDURES
Mice
Pdyn-EGFP transgenic mice (GENSAT, founder line BD193) (Gong et al., 2003)
were crossed with other transgenic mice (as described in the appropriate
figure legends) and maintained on a C57BL/6 background. A full list of
mouse strains is provided in the Supplemental Experimental Procedures. All
experimental manipulations were performed in accordance with protocols
approved by the Harvard Standing Committee on Animal Care following guide-
lines described in the US NIH Guide for the Care and Use of Laboratory
Animals.
Stereotaxic Intracranial Injection
Male and female mice (postnatal day 2–9) were anesthetized with isoflurane
and placed in a small animal stereotaxic frame (David Kopf Instruments). After
puncturing the skin and skull under aseptic conditions, AAVs were injected
(0.5–1 ml total volume) bilaterally through a pulled glass pipette at a rate of
100 nl/min using a UMP3 microsyringe pump (World Precision Instruments).
Depending on the size of the mouse, injection coordinates ranged between
0 to +0.5 mm from bregma, 0.5 to 1.0 mm lateral, and 1.8 to 2.3 mm below
pia for dorsal striatum. After surgical procedures, mice were returned to their
home cage for >21 days to allow for maximal gene expression.
Immunohistochemistry
Brain tissue was fixed using 4% paraformaldehyde and processed using stan-
dard methods, as described in the Supplemental Experimental Procedures,
which also lists all antibodies used. Whole sections were imaged with an
Olympus VS110 slide scanning microscope using a 103 objective. Mosaic im-
ages were automatically constructed by the microscope’s OlyVIA software.
For Figures 1B, 2A, and 2B, high-resolution images of regions of interest
were subsequently acquired with a Leica SP8 X confocal microscope using
a 203 0.75 NA oil immersion objective (Harvard NeuroDiscovery Center).
Images represent maximum intensity projections of 15–25 mm (Figure 1B) or
40–80 mm (Figures 2A and 2B) confocal stacks.
FISH
Mice were deeply anesthetized with isoflurane and decapitated, and their
brains were quickly removed and frozen in tissue freezing medium on dry
ice. Brains were cut on a cryostat (Leica CM 1950) into 30 mm sections,
adhered to SuperFrost Plus slides (VWR), and immediately refrozen.
Samples were fixed 4% paraformaldehyde, processed according to ACD
RNAscope Fluorescent Multiplex Assay manual, and coverslipped with
ProLong antifade reagent (Molecular Probes). Sections were imaged on a
Leica SP8 X confocal microscope using a 633 1.4 NA oil immersion objec-
tive (Harvard NeuroDiscovery Center). Tiled z stacks (3–5 mm) were ob-
tained to cover large areas around patches, visually identified by high
levels of Pdyn signal.
Image Analysis
SPN cell density and EGFP/tdTomato co-localization were determined
using confocal images of sections from Pdyn-EGFP and Pdyn-EGFP;Drd1a-
tdTomato mice stained with the appropriate antibodies, as described in the
Supplemental Experimental Procedures. FISH images were analyzed using a
custom macro in Image J, as described in the Supplemental Experimental
Procedures.
Acute Brain Slice Preparation
Coronal brain slices (300-mm thick) were obtained from 28- to 35-day-old mice
(bothmale and female) using standard techniques, as described in the Supple-
mental Experimental Procedures. Briefly, animals were perfused with ACSF,
brains were sliced in ice-cold choline-based solution, recovered in at 34C
in ACSF, and subsequently maintained at room temperature (20C–22C)
until use.
Electrophysiology
Detailed procedures are available in the Supplemental Experimental Proce-
dures. Briefly, slices were placed in a recording chamber mounted on an up-
right customizedmicroscope (Olympus BX51WI) and continuously superfused
(4 ml/min) with ACSF warmed to 31C–33C for whole-cell voltage-and cur-
rent-clamp recordings. Patch pipettes (2–4 MU) pulled from borosilicate glass
(G150F-3, Warner Instruments) were filled either with ACSF for cell-attached
current clamp recordings, a Cs+-based low Cl internal solution or a Cs+-
based high Cl internal solution (Figures 6A, S7E, and S7F, only) for whole-
cell voltage-clamp recordings, or with a K+-based low Cl internal solutionNefor whole-cell current-clamp recordings. To electrically evoke IPSCs,
simulating electrode pipettes were placed nearby the recorded cell (50–
150 mm) within the same compartment, and a brief pulse (0.5 ms, 20–80 mA)
was delivered at 20-s intervals. To activate ChR2-expressing cells and axons,
light from a 473 nm laser (Optoengine) was focused on the back aperture of the
microscope objective to produce wide-field illumination with brief pulses of
light (2 ms–2 s duration; 0.2–50 mW$mm2 under the objective, see Supple-
mental Experimental Procedures) at 20 s intervals.
UV Uncaging
UV uncaging (Figures S7G, S8C, and S8D) was carried out as described in
Banghart and Sabatini (2012) (see Supplemental Experimental Procedures).
Collimated UV illumination was applied over the entire field of view, which typi-
cally covered an entire patch.
Electrophysiological Data Acquisition and Analysis
Membrane currents and potentials were amplified and low-pass filtered at 3
kHz using a Multiclamp 700B amplifier (Molecular Devices), digitized at 10
kHz, and acquired using National Instruments acquisition boards and a
custom version of ScanImage written in MATLAB (Mathworks). Electrophysi-
ology and imaging data were analyzed offline using Igor Pro (Wavemetrics),
custom MatLab scripts, and ImageJ (NIH). In figures, current-clamp and
voltage-clamp traces represent the averaged waveform of 3–5 consecutive
acquisitions. Peak amplitudes were calculated by averaging over a 2-ms win-
dow around the peak. To determine magnitude of modulation by enk, the peak
amplitude of six consecutive IPSC amplitudes were averaged once the IPSC
reached a stable plateau (4 to 5 min for enk and DAMGO and 6–8 min for
SNC-80). IPSC amplitudes were normalized to baseline averages (six consec-
utive traces immediately prior to drug application).
Statistical Tests
For electrophysiological recordings with bath applications of drugs, signifi-
cance of modulation was tested by comparing the IPSC peak amplitudes
following drug application to the baseline amplitudes using Wilcoxon’s sign-
ranked test. In the text, this p value appears with the average normalized
IPSC and ‘‘n’’ values for a given condition. Wilcoxon’s sign-ranked test was
also used to compare IPSC amplitudes induced when stimulating electrode
is placed inside or outside the patch (Figure 3). To compare the expression
levels of Pdyn, Oprm1, and Oprd1 transcripts in each patch or matrix cell,
we used the two-sample Kolmogorov-Smirnov test (Figure S6). For all other
comparisons between different datasets (both images and electrophysiolog-
ical data), summary values were reported asmean ± SEM and were compared
to each other using the Mann-Whitney U test. For all comparisons, p values
smaller than 0.05 were denoted with an asterisk.
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